Condition
mCRPC or Advanced/Metastatic Solid Tumors
Total Trials
3
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (2)
Trial Status
Recruiting2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07533708Phase 1RecruitingPrimary
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
NCT07719361Phase 1Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT03453528Not ApplicableCompleted
Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors
Showing all 3 trials